Home » Stocks » FLDM

Fluidigm Corporation (FLDM)

Stock Price: $4.63 USD -0.07 (-1.49%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $4.48 -0.15 (-3.24%) Apr 16, 7:25 PM
Market Cap 347.08M
Revenue (ttm) 138.14M
Net Income (ttm) -53.02M
Shares Out 72.04M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $4.63
Previous Close $4.70
Change ($) -0.07
Change (%) -1.49%
Day's Open 4.73
Day's Range 4.49 - 4.70
Day's Volume 1,625,158
52-Week Range 1.89 - 12.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...

1 week ago - GlobeNewsWire

Innovation is risky, and these companies are all in.

Other stocks mentioned: GH, NNOX
4 weeks ago - The Motley Fool

The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's (NASDAQ: FLDM) AZOVA COVID-19 test collection kit for use with the company's Advanta Dx SARS-CoV-2 RT-PCR Assay on its Biomark...

1 month ago - Benzinga

The company reported disappointing fourth-quarter results.

2 months ago - The Motley Fool

Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

2 months ago - GlobeNewsWire

PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China PLT and Fluidigm Collaborate on Submission to the Natio...

2 months ago - GlobeNewsWire

On Wednesday, February 10, Fluidigm (NASDAQ:FLDM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

2 months ago - Benzinga

Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

2 months ago - GlobeNewsWire

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

The company is now cleared to sell its saliva-based COVID-19 test in Europe.

2 months ago - The Motley Fool

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: SEEL, ADMP, BCRX
2 months ago - Benzinga

Fluidigm (FLDM) stock is soaring higher on Friday following an update for the company's saliva-based novel coronavirus test. The post FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today appe...

2 months ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

3 months ago - GlobeNewsWire

Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for  Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Ce...

3 months ago - GlobeNewsWire

Investors focused on tech growth stocks may want to consider the following businesses, as their quarterly revenue and net income have advanced strongly on a year-over-year basis.

Other stocks mentioned: IPHI, TENB
4 months ago - GuruFocus

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

4 months ago - GlobeNewsWire

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: FLDM shares.

4 months ago - GlobeNewsWire

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Fluidigm (FLDM).

4 months ago - Zacks Investment Research

Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

4 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 20, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm" or "t...

4 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fluidigm Corporation (NASDAQ: FLDM) alle...

4 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm” or "the Company") (NASDAQ: FLDM) and ...

4 months ago - Business Wire

New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February...

4 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

4 months ago - Newsfile Corp

Weill Cornell Medicine Researchers Utilize Fluidigm Hyperion Imaging System to Identify a Phenotype of Immune Cell Activity Distinct from Other Lung Infections

4 months ago - GlobeNewsWire

LOS ANGELES, Nov. 18, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on b...

4 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

4 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FLDM #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action fil...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February 7, 2019 and Novemb...

5 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - November 13, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a sec...

5 months ago - Newsfile Corp

NEW YORK, Nov. 10, 2020 /PRNewswire/ --Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

5 months ago - GlobeNewsWire

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - November 6, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February ...

5 months ago - Newsfile Corp

Fluidigm (FLDM) delivered earnings and revenue surprises of 150.00% and 19.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Cramer on four coronavirus testing stocks worth owning

YouTube video

"I bet the testing stocks have a lot more room to run," the "Mad Money" host said.

Other stocks mentioned: ABT, DGX, HOLX, LH, PKI, QDEL, TMO
5 months ago - CNBC Television

Shares of Fluidigm (NASDAQ:FLDM) rose 1.47% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 133.33% over the past year to $0.03, which beat the e...

5 months ago - Benzinga

Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Fu...

5 months ago - GlobeNewsWire

25 Trials Utilizing Mass Cytometry Initiated in 2020 25 Trials Utilizing Mass Cytometry Initiated in 2020

5 months ago - GlobeNewsWire

Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution

5 months ago - GlobeNewsWire

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fluidigm Corporation ("Fluidigm" or the "Company") (NASDAQ: FLDM). Such investors are advised to c...

5 months ago - PRNewsWire

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

About FLDM

Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instrume... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 10, 2011
CEO
Stephen Linthwaite
Employees
627
Stock Exchange
NASDAQ
Ticker Symbol
FLDM
Full Company Profile

Financial Performance

In 2020, Fluidigm's revenue was $138.14 million, an increase of 17.83% compared to the previous year's $117.24 million. Losses were -$53.02 million, -18.17% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Fluidigm stock is "Strong Buy." The 12-month stock price forecast is 10.33, which is an increase of 123.11% from the latest price.

Price Target
$10.33
(123.11% upside)
Analyst Consensus: Strong Buy